Targeted Therapy, Untargeted Rash: Insights From a GRAPPA Workshop on Immune Shifts in Psoriatic Disease
- 15 June 2026
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (Suppl 2) , 37-40
Abstract
The increasing use of targeted immunomodulatory therapies for psoriasis and atopic dermatitis has transformed disease management. However, paradoxical and treatment-induced cutaneous adverse and musculoskeletal events are being increasingly recognized that often mimic or deviate from the primary disease phenotype. This review summarizes current evidence on the clinical manifestations, underlying pathophysiological mechanisms, and therapeutic strategies for biologic-induced cutaneous and articular reactions in immune-mediated dermatoses. We highlight reactions associated with tumor necrosis factor, interleukin (IL)-17, IL-23, and IL-4/IL-13 inhibitors, discussing diagnostic challenges and immunologic shifts underlying these phenomena. Recognition of these distinct entities is critical to avoid misinterpretation as treatment failure and to optimize patient care through tailored management strategies and shared decision making.Keywords
This publication has 39 references indexed in Scilit:
- Psoriasis Risk in Patients With Atopic Dermatitis Treated With DupilumabJAMA Dermatology, 2025
- Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment ApproachClinical Case Reports, 2024
- Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisJAMA Dermatology, 2024
- Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysisDermatology and Therapy, 2023
- Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin‐4/13 InhibitorArthritis & Rheumatology, 2023
- Dupilumab-Associated Arthritis: A Dermatology-Rheumatology PerspectiveAmerican Journal of Clinical Dermatology, 2023
- TNF-α inhibitor–induced psoriasis: A decade of experience at the Cleveland ClinicJournal of the American Academy of Dermatology, 2020
- Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 TherapyJAMA Dermatology, 2019
- Psoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with UstekinumabDermatology and Therapy, 2016
- Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigationArchives of Dermatological Research, 2008